# Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma

> **NCT07498907** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 192 (estimated)

## Conditions studied

- Upper Tract Urothelial Carcinoma

## Interventions

- **DRUG:** Disitamab Vedotin (RC48)
- **RADIATION:** radiotherapy
- **DRUG:** Gemcitabine (1000 mg/m2)
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT07498907
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2029-05-01
- **Final completion:** 2034-03-01
- **Target enrollment:** 192 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07498907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07498907, "Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07498907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*